Co‑expression of the carbamoyl‑phosphate synthase 1 gene and its long non‑coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma

Ma,Sen‑Lin; Li,Ai‑Jun; Hu,Zhao‑Yang; Shang,Fu‑Sheng; Wu,Meng‑Chao

doi:10.3892/mmr.2015.4435

Co‑expression of the carbamoyl‑phosphate synthase 1 gene and its long non‑coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma

Authors:
- Sen‑Lin Ma
- Ai‑Jun Li
- Zhao‑Yang Hu
- Fu‑Sheng Shang
- Meng‑Chao Wu
View Affiliations

Affiliations: Department of Second Special Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Tumor Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310002, P.R. China, Department of Experiments, Shanghai Fu Neng Biological Technology Co., Ltd., Shanghai 200237, P.R. China
Published online on: October 13, 2015 https://doi.org/10.3892/mmr.2015.4435
Pages: 7915-7926
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mechanisms leading to high rates of malignancy and recurrence of human intrahepatic cholangiocarcinoma (ICC) remain unclear. It is difficult to diagnose and assess the prognosis of patients with ICC in the clinic due to the lack of specific biomarkers. In addition, long non‑coding RNAs (lncRNAs) have been reported to serve important roles in certain types of tumorigenesis however a role in ICC remains to be reported. The aim of the current study was to screen for genes and lncRNAs that are abnormally expressed in ICC and to investigate their biological and clinicopathological significance in ICC. The global gene and lncRNA expression profiles in ICC were measured using bioinformatics analysis. Carbamoyl‑phosphate synthase 1 (CPS1) and its lncRNA CPS1 intronic transcript 1 (CPS1‑IT1) were observed to be upregulated in ICC. The expression of CPS1 and CPS1‑IT1 was measured in 31 tissue samples from patients with ICC and a number of cell lines. The effects of CPS1 and CPS1‑IT1 on the proliferation and apoptosis of the ICC‑9810 cell line were measured. In addition, the clinicopathological features and survival rates of patients with ICC with respect to the gene and lncRNA expression status were analyzed. CPS1 and CPS1‑IT1 were co‑upregulated in ICC tissues compared with non‑cancerous tissues. Knockdown of CPS1 andor CPS1‑IT1 reduced the proliferation and increased the apoptosis of ICC‑9810 cells. Additionally, clinical analysis indicated that CPS1 and CPS1‑IT1 were associated with poor liver function and reduced survival rates when the relative expression values were greater than 4 in cancer tissues. The comparisons between the high CPS1 expression group and the low expression group indicated significant differences in international normalized ratio (P=0.048), total protein (P=0.049), indirect bilirubin (P=0.025), alkaline phosphatase (P=0.003) and disease‑free survival (P=0.034). In addition, there were differential trends in CA19‑9 (P=0.068), globulin (P=0.052) and total bilirubin (P=0.066). The comparisons between the high CPS1‑IT1 expression group and the low expression group indicated significant differences in lymphatic invasion (P=0.045), carbohydrate antigen 19‑9 (P=0.044), disease‑free survival (P=0.026), and non‑significant differential trends in alkaline phosphatase were observed (P=0.085). In conclusion, CPS1 and CPS1‑IT1 may serve an important role in ICC development by promoting the proliferation of ICC cells. Furthermore, CPS1 and CPS1‑IT1 were associated with poor liver function and reduced survival rates. Thus, CPS1 and CPS1‑IT1 may be potential prognostic indicators for patients with ICC.

View Figures

View References

1	Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X and Willenbring H: Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 122:2911–2915. 2012. View Article : Google Scholar : PubMed/NCBI
2	Sekiya S and Suzuki A: Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 122:3914–3918. 2012. View Article : Google Scholar : PubMed/NCBI
3	Khan SA, Toledano MB and Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB Oxf. 10:77–82. 2008. View Article : Google Scholar
4	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
5	Shaib YH, Davila JA, McGlynn K and El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol. 40:472–477. 2004. View Article : Google Scholar : PubMed/NCBI
6	Shimoda M and Kubota K: Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol. 13:1500–1504. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, Gaudio E and Alvaro D: Cholangiocarcinoma: Epidemiology and risk factors. Transl Gastrointest Cancer. 1:21–32. 2012.
8	Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
9	Tan JC, Coburn NG, Baxter NN, Kiss A and Law CH: Surgical management of intrahepatic cholangiocarcinoma–a population-based study. Ann Surg Oncol. 15:600–608. 2008. View Article : Google Scholar
10	de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, et al: Intrahepatic cholangiocarcinoma: An international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 29:3140–3145. 2011. View Article : Google Scholar : PubMed/NCBI
11	Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, et al: Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 248:84–96. 2008. View Article : Google Scholar : PubMed/NCBI
12	Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ and Chung JB: The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: Association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 16:3048–3056. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shimada K, Sano T, Nara S, Esaki M, Sakamoto Y, Kosuge T and Ojima H: Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. Surgery. 145:411–416. 2009. View Article : Google Scholar : PubMed/NCBI
14	Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, et al: Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 144:829–840. 2013. View Article : Google Scholar : PubMed/NCBI
15	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
16	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wapinski O and Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361. 2011. View Article : Google Scholar : PubMed/NCBI
18	Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, Eret V, Finek J, Chottova-Dvorakova M, Babjuk M, Novak K and Stolz J: Differential display code 3 (DD3PCA3) in prostate cancer diagnosis. Anticancer Res. 30:665–670. 2010.PubMed/NCBI
19	Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X and Tao Z: The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol. 90:97–100. 2011. View Article : Google Scholar
20	Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
21	Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 29:1810–1816. 2012. View Article : Google Scholar
22	Chakravadhanula M, Ozols VV, Hampton CN, Zhou L, Catchpoole D and Bhardwaj RD: Expression of the HOX genes and HOTAIR in atypical teratoid rhabdoid tumors and other pediatric brain tumors. Cancer Genet. 207:425–428. 2014. View Article : Google Scholar : PubMed/NCBI
23	Park JY, Lee JE, Park JB, Yoo H, Lee SH and Kim JH: Roles of Long Non-Coding RNAs on Tumorigenesis and Glioma Development. Brain Tumor Res Treat. 2:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
24	Mian A and Lee B: Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism. Trends Mol Med. 8:583–589. 2002. View Article : Google Scholar : PubMed/NCBI
25	Mei D, Song H, Wang K, Lou Y, Sun W, Liu Z, Ding X and Guo J: Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med Oncol. 30(709)2013. View Article : Google Scholar : PubMed/NCBI
26	Sun W, Wu Y, Yu X, Liu Y, Song H, Xia T, Xiao B and Guo J: Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance. Tumour Biol. 34:2697–2701. 2013. View Article : Google Scholar : PubMed/NCBI
27	Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D and Zhang Y: Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol. 45:17–23. 2010. View Article : Google Scholar
28	Wang Y, Hong Y, Li M, Long J, Zhao YP, Zhang JX, Li Q, You H, Tong WM, Jia JD and Huang J: Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. PLoS One. 8:e824262013. View Article : Google Scholar : PubMed/NCBI
29	Yao C, Oh JH, Oh IG, Park CH and Chung JH: [6]-Shogaol inhibits melanogenesis in B16 mouse melanoma cells through activation of the ERK pathway. Acta Pharmacol Sin. 34:289–294. 2013. View Article : Google Scholar
30	Zhang H, Zhou WC, Li X, Meng WB, Zhang L, Zhu XL, Zhu KX, Bai ZT, Yan J, Liu T, et al: 5-Azacytidine suppresses the proliferation of pancreatic cancer cells by inhibiting the Wntβ-catenin signaling pathway. Genet Mol Res. 13:5064–5072. 2014. View Article : Google Scholar : PubMed/NCBI
31	Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, et al: Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intra-hepatic cholangiocarcinoma. Hepatology. 56:1792–1803. 2012. View Article : Google Scholar : PubMed/NCBI
32	Bonnefont J, Laforge T, Plastre O, Beck B, Sorce S, Dehay C and Krause KH: Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation. Cell Death Differ. 18:293–303. 2011. View Article : Google Scholar :
33	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
34	Zhang X, Sun S, Pu JK, et al: Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis. 48:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
35	Khachane AN and Harrison PM: Mining mammalian transcript data for functional long non-coding RNAs. PLoS One. 5:e103162010. View Article : Google Scholar : PubMed/NCBI
36	Morris SM Jr: Regulation of enzymes of urea and arginine synthesis. Annu Rev Nutr. 12:81–101. 1992. View Article : Google Scholar : PubMed/NCBI
37	Schofield JP: Molecular studies on an ancient gene encoding for carbamoyl-phosphate synthetase. Clin Sci (Lond). 84:119–128. 1993. View Article : Google Scholar
38	Liu TH, Li DC, Gu CF and Ye SF: Carbamyl phosphate synthetase I. A novel marker for gastric carcinoma. Chin Med J (Engl). 102:630–638. 1989.
39	Liu H, Dong H, Robertson K and Liu C: DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am J Pathol. 178:652–661. 2011. View Article : Google Scholar : PubMed/NCBI
40	Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M and Gruenberger T: Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 15:2787–2794. 2008. View Article : Google Scholar : PubMed/NCBI
41	Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S and Kubo S: Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 15:583–589. 2008. View Article : Google Scholar
42	Patel AH, Harnois DM, Klee GG, LaRusso NF and Gores GJ: The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 95:204–207. 2000. View Article : Google Scholar : PubMed/NCBI
43	Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar
44	Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, et al: Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol. 49:207–216. 2008. View Article : Google Scholar : PubMed/NCBI
45	Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, Schmid KW and Baba HA: GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia. 9:159–165. 2007. View Article : Google Scholar : PubMed/NCBI